8-K: LAVA Therapeutics Acquired, Delists from Nasdaq

LAVA Therapeutics N.V. announced the successful completion of XOMA Royalty Corporation's tender offer, leading to its delisting from Nasdaq and a change in company control.

Summary

• XOMA Royalty Corporation successfully completed its tender offer to acquire LAVA Therapeutics N.V.
• 22,877,463 shares, approximately 87% of outstanding shares, were validly tendered by the initial expiration time of November 12, 2025.
• The minimum tender condition for the offer was satisfied.
• Buyer accepted and paid for all validly tendered shares on November 13, 2025, at $1.04 per share plus one Contingent Value Right (CVR).
• A subsequent offering period commenced on November 13, 2025, and will expire on November 20, 2025, allowing remaining shareholders to tender shares.
• LAVA Therapeutics has submitted notice to Nasdaq for voluntary delisting of its common shares.
• Trading on Nasdaq Global Select Market is expected to be suspended on or about November 21, 2025, with Nasdaq filing for removal from listing around November 24, 2025.
• LAVA Therapeutics is now a majority-owned subsidiary of XOMA Royalty Corporation.

Sentiment

Score: 7

Explanation: The successful completion of the tender offer provides a clear outcome for shareholders, offering a cash payment and a CVR. While delisting removes public trading, the acquisition by XOMA Royalty provides a new strategic direction for LAVA's assets. The CVR introduces some uncertainty regarding future value.

Positives

• The tender offer successfully met its minimum condition and closed, providing liquidity and a defined exit for tendering shareholders.
• Shareholders received $1.04 per share in cash, plus a Contingent Value Right (CVR) for potential future payments.
• The acquisition by XOMA Royalty Corporation provides a clear path forward for the company's assets and operations.

Negatives

• LAVA Therapeutics' common shares will be delisted from Nasdaq, removing public trading access for remaining shareholders.
• Shareholders who did not tender their shares by the initial deadline will have limited liquidity options after delisting.
• The value of the Contingent Value Right (CVR) is uncertain and may not result in any value to shareholders.

Risks

• The transactions may not be completed in a timely manner, or at all, which could adversely affect LAVA's business and share price.
• There is a risk of delay or failure of the conditions of the Offer to be satisfied (or waived).
• The possibility that competing offers will be made.
• Significant costs are associated with the transactions.
• Shareholder or other litigation in connection with the transactions may result in significant costs of defense, indemnification, and liability.
• Activities related to the CVR Agreement, including new forms thereof, may not result in any value to LAVA's shareholders, including payments related to the resolution of certain potential liabilities.
• Prior to the completion of the transactions, LAVA's or XOMA Royalty's business may experience significant disruptions due to transaction-related uncertainty.
• The announcement and pendency of the transactions may make it more difficult to establish or maintain relationships with employees, manufacturers, suppliers, vendors, or business partners.
• The occurrence of any event, change, or other circumstance that could give rise to the termination of the purchase agreement.
• Potential adverse effects on LAVA's business condition and results from general economic and market conditions and overall fluctuations in the United States and international equity markets, including as a result of inflation, heightened interest rates, recent and potential future pandemics and other health crises, and hostilities (e.g., Russian invasion of Ukraine, Middle East conflict).

Future Outlook

The company will become a private entity under XOMA Royalty Corporation. The future operations will be guided by XOMA Royalty, with a focus on LAVA's biopharmaceutical pipeline, including its Gammabody platform and partnered programs with Johnson & Johnson and Pfizer. The value of the Contingent Value Rights (CVRs) is subject to future events and may not result in any payments.

Management Comments

• LAVA announced that 22,877,463 of LAVAs common shares, representing approximately 87% of LAVAs outstanding common shares, were validly tendered and not withdrawn prior to the expiration of the initial offering period.
• LAVA also announced today that it has submitted written notice to Nasdaq of its intention to voluntarily delist its common shares from Nasdaq.

Industry Context

This acquisition represents a consolidation within the biopharmaceutical sector, where larger entities or investment firms acquire smaller, innovative companies, often for their pipeline assets or proprietary technology platforms. LAVA's focus on bispecific gamma delta T cell engagers and its partnerships with major pharmaceutical companies like Johnson & Johnson and Pfizer highlight the ongoing interest in novel immuno-oncology and targeted therapy approaches. The acquisition by XOMA Royalty, a company focused on royalty streams, suggests an interest in the long-term value generation from LAVA's clinical-stage assets.

Comparison to Industry Standards

• The acquisition price of $1.04 per share plus a CVR is specific to LAVA's valuation and pipeline stage. Without detailed financial performance or comparable deal metrics for similar clinical-stage biopharmaceutical companies with partnered assets, a direct assessment against global benchmarks is not feasible from the provided filing.
• The structure of the deal, including a CVR, is a common mechanism in biopharmaceutical acquisitions to bridge valuation gaps and share future upside or downside risk, particularly for companies with early-stage or unproven assets.

Management Changes

Corporate Governance

Stakeholder Impact

• Shareholders: Those who tendered shares received $1.04 cash per share and a CVR. Remaining shareholders will hold shares in a privately-owned company, losing public market liquidity, and the value of CVRs is uncertain.
• Employees: The filing does not explicitly mention employee impact, but a change of control can often lead to organizational restructuring or changes in compensation/benefits.
• Customers/Partners: The company's biopharmaceutical partnerships (Johnson & Johnson, Pfizer) are expected to continue under the new ownership, but the change in control could introduce new strategic priorities or operational adjustments.
• Creditors: No specific impact mentioned, but the change in ownership structure could alter the company's financial profile and access to capital markets.

Next Steps

• Shareholders who have not yet tendered their common shares may do so during the subsequent offering period, which expires on November 20, 2025.
• LAVA's common shares are expected to be suspended from trading on Nasdaq on or about November 21, 2025.
• Nasdaq is expected to file a notification of removal from listing with the SEC on or about November 24, 2025.

Key Dates

Recommendation

For shareholders who have not yet tendered, the recommendation is to hold and tender shares during the subsequent offering period. The offer provides a fixed cash price and a CVR, which is a defined exit strategy. Once the company delists, liquidity will be severely limited, making it difficult to sell shares. Therefore, participating in the tender offer is the most prudent action to realize value. For those who have already tendered, the transaction is complete. For new investors, the stock is effectively being taken private, so there is no public market to 'buy' into for long-term investment.

Keywords

LAVA Therapeutics, XOMA Royalty Corporation, Tender Offer, Acquisition, Delisting, Nasdaq, Change of Control, Biopharmaceutical, Gammabody platform, Contingent Value Right, LVTX